ç®æ¬¡
- ã¹ãŒããŒNIPT100ïŒç¬¬3äžä»£NIPTïŒãšã¯ïŒ
- ã¹ãŒããŒNIPT100ïŒç¬¬3äžä»£NIPTïŒã®ä¿¡é Œæ§ã¯ã©ããªã®ïŒ
- éºäŒåå€ç°ã¯ã©ãããçŸæ£ãæ€æ»ã§ããã®ïŒ
- æè²äœãéºäŒåã®ç°åžžã¯ãªãèµ·ããã®ïŒïŒ
- åŸ®çŽ°æ¬ å€±çå矀ãšã¯ïŒ
- ã¹ãŒããŒNIPTã®è²»çšã¯ïŒ
- ããããã質å
ã¹ãŒããŒNIPT100ïŒåäžéºäŒçŸæ£NIPTïŒ
åœé¢ã§ã¯ããã¹ãŠã®NIPTæ€æ»ã9é±0æ¥ãããåãããããŸããïŒã€ã«ãããé€ãïŒ
ã¹ãŒããŒNIPTïŒéºäŒæ§çŸæ£NIPTïŒãšã¯ïŒ
ïŒ2020幎1æãã100éºäŒåã®2000ã®ç çããªã¢ã³ãïŒå€ç°ïŒã«ããå 倩æ§çŸæ£ãã察象ãšããã¹ãŒããŒNIPTïŒç¬¬3äžä»£ïŒãåãæ±ãéå§ããŸãã第3äžä»£NIPTã¯äžçã§1瀟ããè¡ã£ãŠããŸãããã€ã«ããVeriseq2ãæäŸããçŽ2.5åã®èšåæè³ãšé«ãæè¡åãå¿ èŠã ããã§ããæ¥æ¬ã§ç¬¬3äžä»£NIPTã¯ããã«ãã¯ãªããã¯ã®ç¬å å¥çŽãšãªã£ãŠããŸããçŸå®¹å€ç§ã»ç®èç§ãªã©ã§NIPTãè¡ãããæ¥æ¬ã®çŸç¶ã«äžçã¯çãã²ãããŠãããããéºäŒå°éå»ã責任ããã£ãŠéå¶ããŠããããã«ãã¯ãªããã¯ãšç¬å å¥çŽã®éã³ãšãªããŸããã
ã¹ãŒããŒNIPTäºäŸ
check!NIPTïŒæ°ååºçå蚺æ/é䟵襲çåºç忀æ»ïŒé¢é£ã³ã©ã
NIPTæåç·ïœåäžéºäŒåçŸæ£ã®NIPT
äœãä»ãŸã§ãšéãã®ãïŒ
ã¹ãŒããŒNIPT100ããåžæã®å Žåã¯ã倫婊ã§ãè¶ããã ããããå€«å©Šã§æ¥é¢ã§ããªãå Žåã¯ãçžè«ãã ãããïŒäºåã«æŠé£æ§ã«å£è
ç²èããåãããã ãããšã§ã奥æ§ã®ã¿ã®ãæ¥é¢ãå¯èœã§ãïŒ
æž¬å®æ¹æ³ãå šãç°ãªãã®ã§ã§ããããšãéããŸãã
ããã«ãã¯ãªããã¯ã§ã¯ããšããš
éºäŒæ§çŸæ£ãæã€ãåãããçãŸããå¯èœæ§ãããã倫婊ãªã®ãã©ãããããããã調ã¹ãéºäŒåæ€æ»ïŒãã£ãªã¢æ€æ»ïŒãæäŸããŠããŸãã
ãã¡ããã芧ãã ãã
327çš®é¡ã®éºäŒåã«ã€ããŠç çå€ç°ã®æç¡ãæ€æ»ããããã«ã§ãã
4äžäººã«äžäººã®ç¢ºçã®åžžæè²äœå£æ§çŸæ£ã ãšä¿å è ïŒãã£ãªã¢ïŒã¯100人ã«äžäººã
10äžäººã«äžäººã ãšä¿å è ã¯158人ã«äžäººã§ãã
ãã®ã倫婊ã®çµã¿åããã§ãåããã«éºäŒæ§çŸæ£ãèµ·ããå¯èœæ§ããããã©ãããæ€èšããæ€æ»ã§ãã
ãã¡ãã®ã倿®µããäžäººïŒïŒäžåãã倫婊ã§äºäººåæã ãšãäºäººç®ã¯ïŒïŒäžåãåèšïŒïŒäžåã§æäŸããŠããŸãããã¡ãã¯ã327çš®é¡ã®éºäŒåæ€æ»ãªã®ã§ãããã¹ãŒããŒNIPTã§ã¯100çš®é¡ã®éºäŒåã®ç çå€ç°ã«ã€ããŠãäž¡èŠªãæ€æ»ãããªããã€ã䞡芪ã«ãªããŠãèµ€ã¡ããã ãã§èµ·ããæ°ççªç¶å€ç°ã«ã€ããŠèª¿ã¹ãããšãã§ããNIPTåºæ¬æ€æ»ãš4çš®é¡ã®åŸ®çŽ°æ¬ å€±æ€æ»ãš100çš®é¡ã®éºäŒåæ€æ»ã§ã倿®µããããŸã§ã®åºæ¬æ€æ»ïŒåŸ®çŽ°æ¬ å€±ã®18äžåã«3äž5åå远å ããã ããšãªã£ãŠããŸãã
èŠããã«ã3äž5ååã®è¿œå ã§ãã£ãªã¢æ€æ»ã®1/3ã«çžåœãããã®ãã§ããŠããŸããã§ãã
ãã£ãªã¢æ€æ»ã¯ã»ããã«ãªã£ãŠãããã1/3ã ãããããšã¯ã§ããŸãããã1/3ã ãšã倫婊ã§ã倿®µ10äžå以äžããŸãããã
ãªã®ã§ãåŸãªãã§ãã
ãŸãããã®100ã®éºäŒåã®ç çå€ç°ãæã£ãŠããŠçºçããªããã£ãªã¢ïŒä¿å è ïŒã®çޝç©çã¯1/50人ãšçµæ§å€ãã§ãã
æž¬å®æ¹æ³ã®éãã«ã€ããŠã®è©³çްã¯ãã¡ããã¯ãªãã¯ããŠã芧ãã ããã
端çã«èšããš
第1äžä»£ã®WGSæ³ã¯ãæ¯åã®DNAãåºå¥ããŠæž¬å®ããããšã¯ã§ããªãã£ãã®ã§ããã第3äžä»£ã ãšãããæ£ç¢ºã«ã§ããããã«ãªããŸããã
ãªã®ã§ãæ£ç¢ºæ§ãæ Œæ®µã«å¢ããŠãããã§ãã
ä»ã®ãšãããåºæ¬æ€æ»ïŒ13ããªãœããŒã»18ããªãœããŒã»21ããªãœããŒïŒãåŸ®çŽ°æ¬ å€±çå矀ã®åœé°æ§ã¯ãŒããšãªã£ãŠããŸãã
å®ã¯å æ¥ãäžåµæ§åçå ãªã®ã«ãèå ã®æ°ããäžäººãã£ãŠééããŠæžããŠããŸã£ããã§ãããã
ã€ã«ããããã¯äœãèšãããªãã£ãã®ã§ããã第ïŒäžä»£ã®äŒç€Ÿã®ã»ãããã¯ãååã§ããïŒãã£ãŠã°ãã¡ãããŸããïŒ
åãDNAåãªã®ã«ããªãã°ããŠããŸã£ãã®ããªïŒãšæãã€ã€ãæåããããŸããããããããéããã§ãã
é£ãããšæããŸãããã¡ãã£ãšèããŠãã ããã
DNAã¯ãã®ãŸãŸã§ã¯åŸ®éãªã®ã§æž¬å®ã§ããŸããã
ããããPCRïŒéºäŒåãå¢å¹
ãããéçšïŒãšããããæ¹ã§åçã«å¢ãããŠæž¬å®ããããšãã§ããããã«ãªããŸãã
ãã®PCRã®ãšãã«ãå¢ããããéšåãå¢ãã«ããéšåããåºãŠãããã§ãã
PCRã§ã¯ããããããŠå ç±ãããâã2æ¬éã®DNAã倿§ããŠ1æ¬ã«ãªããâãå·åŽãããâãå¹é€æ¶²ã®äžã®çžè£çãªå¡©åºïŒã¢ããã³ãšããã³ãã°ã¢ãã³ãšã·ãã·ã³ïŒããã£ã€ãïŒã¢ããŒãªã³ã°ãšãããŸãïŒãâã2æ¬éãã§ããããšããæãã§é²ããŠããã®ã§ãã
DNAã®å¡©åºé
åã«ãããã¢ãã¬ãŒã·ã§ã³ã«æé©ãªç°å¢ã埮åŠã«ç°ãªããŸãã®ã§ããããå
šã²ãã åãæ¡ä»¶ã§è¡ãããã§ããããã©ãããŠãå¢ããããéšåãšå¢ãã«ããéšåãåºãŠãããã§ãã
ããšãã°ããéšåAã¯åã«å¢ããŠãBã¯1.2åã«ããå¢ããªãããšããããããã°ãã€ããå¡©åºé åã«ããèµ·ãããŸãã
第1äžä»£ã®WGSã«ããNIPTã§ã¯ããããã°ãã€ãã«å¯ŸããŠå¢ãããããå¢ãã«ããã«ããããŠåçã«ããä¿æ°ããããããšã§æŒç®ããŠçµæãåºããŠããããšãèãããã ããããããšæããŸãã
第2äžä»£ã¯ãç¯çœªææ»ãªã©ã«ã䜿ãããããåã 人ã®åŸ®åŠãªéããã§ããäžå¡©åºå€åïŒSNPïŒãå©çšããŠãã®æçã®å Žæãç¹å®ããå¢ããããã®ã°ãã€ããå¹³ãã«ããŠããŸããããã¡ãã¯ããšããšã®ãªãªãžãã«ã®èå æçã¯ãªããªã£ãŠããŸãã人工çã«å¢ãããã³ããŒã ããæ€æ»ããŠããŸããèªã¿åãæ·±åºŠã¯ç¬¬1äžä»£ããå€ãã§ãã
深床ããšããã®ã¯äœåèªãã ãïŒãšããããšã§ãã
50ãªãå
šäœã50åã¿ãããšããããšã§ãã
å€ããã°å€ãã»ã©è¯ãã®ã§ãããå€ããã°å€ãã»ã©ã³ã¹ãããããã®ãšãå€ããã°å€ãã»ã©æå³ã®ãªããã®ããããããæå³ãããããã«ãæŸã£ãŠããŸãããšããé£ç¹ããããŸãã
第3äžä»£ã§ã¯ãèªã¿åãæ·±åºŠãããã«äžããŸããããããŠãããã¡ããã«ç±æ¥ããDNAããæ£ç¢ºã«ãåããããã«ãããã¡ããã®DNAæçã¯ãããããã®DNAæçããããçãããããåŸãããæçã®ãµã€ãºïŒå€§ãããå¡©åºé åã®æ°ïŒã枬å®ããããšã§ãã£ãããšèµ€ã¡ããã®DNAã ããéžå¥ããŠæž¬å®ãã§ããããã«ãªããŸããã
DNAã¯ãã¹ãã³ãšããããã¿ã³ãã¯ã«2éãããã§1.75å転ãŸãã€ããŠãé£ã®ãã¹ãã³ã«è¡ããŸã§ã«å¹³ããªéšåãããããŸãé£ã®ãã¹ãã³ã«å·»ãä»ãããšããããã¡ã§ååšããŠããŸããããããã ãŒã£ãšçž®ãŸã£ãŠæè²äœã«ãªãã®ã§ãã
ãã¹ãã³ã«å¯Ÿãã説æã¯ãã¡ããã¯ãªãã¯ããŠã芧ãã ããã
现èãå£ãããšãã«DNAãæçåãããã®ã§ãããããã¡ããã®DNAã¯ããã®ãã¹ãã³ãšãã¹ãã³ã®éã®ããåºãã®éšåã匱ãããã146å¡©åºå¯Ÿããããããªããã§ãããæ¯ããã®ã»ã«ããªãŒDNAã¯ãããã«å¯ŸããŠ180-200ãããã¯ãããŸãã
ãã®ãµã€ãºã®éãã¯æããããã£ãŠããã®ã§ããã第1äžä»£ã§ã¯æè¡çã«å®æ§ïŒããããªãããšããæ§è³ªã ããã¯ããããšã宿§çãªæ€æ»ãšãããŸãïŒããã§ããªãã£ããã§ãã
ãšãããã第2äžä»£ã第3äžä»£ãšæ¹è¯ãããŠãããã¡ã«ãæ£ç¢ºããå¢ããŠã第3äžä»£ã§ã¯æçã®ãµã€ãºãã¯ãã£ãŠåãåºãããšãã§ããããã«ãªã£ããããçãèµ€ã¡ããã®åã ããåãåºããŠæ€æ»ããããšãå¯èœãšãªããæ£ç¢ºããå¢ããŸããã
ãã®ããã«ããæšçãããããŠPCRããããããšããæšçPCRïŒã¿ãŒã²ããPCRïŒãšåŒã³ãŸãã
ä»ãŸã§ã®ç¬¬1äžä»£ïŒWGSæ³ïŒã€ã«ãããªã©ïŒã第2äžä»£ïŒããã©ãªã©ïŒãšæ¯ã¹ã衚ãäœããŸããã®ã§ã芧ãã ããã
ã¡ãªã¿ã«ãããåœã§è¡ãããŠããNIPTã¯ãèªå¯æœèšã®ã»ãšãã©ã¯ç¬¬1äžä»£ïŒäž»ã«ã·ãŒã±ãã ãå°ãªããã€ã«ããïŒã§ã第2äžä»£ã®ããã©ã¯ã»ãšãã©æ¡çšãããŠããŸãããç¡èªå¯ïŒèªå¯å€ïŒæœèšãã»ãšãã©ã第1äžä»£ã®WGSæ³ã§ãã
第3äžä»£NIPT | 第2äžä»£ ïŒSNP-based NIPTïŒ | 第1äžä»£ ïŒWhole Genome SequencingïŒ | |
---|---|---|---|
æšçãšããæ¹æ³ | æšçé åç±æ¥ã®cfDNAæç㮠溶液å ãã€ããªãã€ãŒãŒã·ã§ã³ã» ãã£ãã㣠| æšçé åã®ãã«ããã¬ãã¯ã¹ PCRå¢å¹ | æšçãªã |
ãªãªãžãã«èå æç | ããšããšã®æçã æ¯äœè¡æ¶²ãããã£ãã㣠| 䜿çšããªã.æšçé åã®PCRç£ç© ã¯ããŒã³ã䜿çšã | ããšããšã®æçãæ¯äœè¡æ¶²ãã ãã£ãã㣠|
å®éæ³ | 次äžä»£ã·ãŒã¯ãšã³ãµãŒãçšãã ã»ã«ããªãŒDNAã® ãã«ããšã³ãžã³è§£æïŒå®éïŒ | ãããã¿ã€ãåæ§æãš ã¢ãã«é©å | ãã³ã»ãã©ã°ã¡ã³ããèšæž¬ãã è§£ææ¹æ³ïŒå®æ§ïŒ |
PCR ã«ããéè€ | PCRã§éè€ãã ç£ç©ãé€å€ã㊠解æå¯èœ | äžå¯ | èªå深床äžè¶³ ã®ããäžå¯ |
PCRãšã©ãŒ | PCRãšã©ãŒäŒæã æ€åºã»ç·©åã§ãã | äžå¯ | èªå深床äžè¶³ ã®ããäžå¯ |
èå åç» | éåžžã«æ£ç¢ºã« èå åç»ã 枬å®å¯èœ | å¯èœãFF㯠ã¢ãã«é©åã® äžéšã§ããã 粟床ã¯äœã | å
æ¬çã¢ãã« é©åãçšãã æšå®å€ |
枬å®ããã«ã®æ¡åŒµæ§ | ã¢ãã»ã€ã æ¿çž®ããããã® ä»å ãããŒãã èšèšããããšã«ãã£ãŠ ä»ã®æ¡ä»¶ã«æ¡åŒµã 容æã§ãã | éåžžã«é£ããã ãã¹ãŠã®é åã§ SNPãèŠã€ããããš ã¯ã§ããªã | ä»ã®ç°æ°æ§ã åŸ®å°æ¬ 倱ãžã® æ¡å€§ã¯å®¹æã§ãããã 粟床ããã³ PPVã¯äœãã |
åŸ®çŽ°æ¬ å€± | éåžžã«é«ç²ŸåºŠã çŸåš4çš®é¡ã® åŸ®çŽ°æ¬ å€±ã«å¯Ÿå¿ã 1 Mbãšãããµã€ãº ã®åŸ®çŽ°æ¬ å€±ãæ€åºã | 粟床ããããã éœæ§çäžçãäœãã | ç²ŸåºŠãæªãã ïŒMbæªæºã®å°ããª æ¬ å€±ã«å¯ŸããæåºŠ ãäœãã |
ãããã·ã³ã°ã»ãã€ã³ | å¯èœãæ¶å€±ããŠãã 4é±éåŸã«æ€äœ æ¡åã | äžå¯ | éåžžã¯äžå¯ã |
â»èå
åç»ã¯å€ããã°å€ãã»ã©æ£ç¢ºã«æž¬ããŸãã
é¢é£èšäºïŒãèµ€ã¡ããã®DNAãå°ãªããšã©ããªãã®ïŒãéºäŒåãšã¯ãPCRãšã¯ãã»ã«ããªãŒDNAãšã¯ãåžžæè²äœãšã¯ãSNPäžå¡©åºå€åã«ã€ããŠãããªãœããŒãDNAã®æ§é æ°ççªç¶å€ç°ãåŸ®çŽ°æ¬ å€±ãéºäŒåæ€æ»ãšã¯ãéºäŒæ§çŸæ£ãšã¯
ä»ç€Ÿã®NIPTæ€æ»ãšã®éã
æ¹è¯çãªã®ã§ç²ŸåºŠãäžãã£ãŠããŸããã
第1äžä»£ïŒWGSæ³ïŒã€ã«ãããªã©ïŒã®æ¹è¯çã§ãã第2äžä»£ïŒããã©ãã¢ãªãªãµïŒãšã®éãã2019幎ã®ãšãŒãããã®äººé¡éºäŒåŠäŒESHGã§çºè¡šããããã®ãã衚ãäœããŸããã®ã§ã芧ãã ããã
P01.69A Half decade experience: karyotyping, aCGH or NIPT – changes in prenatal testing strategy
E. E.
Kuznetsova, V. Gnetetskaya, M. Ermakova, M. Kurtser, Y. Tarasova Kuznetsova, V. Gnetetskaya, M. Ermakova, M. Kurtser, Y. Tarasova
Mother and Child, Moscow, Russian Federation
çäŸæ° | ||||||
---|---|---|---|---|---|---|
NIPTãã¹ã | äœãªã¹ã¯ | é«ãªã¹ã¯ | ç¢ºå®æ€æ»ïŒéœæ§çäžçïŒ | åœéœæ§ | åœé°æ§ | 䟵襲ã®ãã æ€æ»ãæåŠ |
ããã©ã ïŒç¬¬2äžä»£2016ïœïŒ | 3381 | 191 | 91ïŒ61ïŒ ïŒ | 58ïŒ38ïŒ ïŒ | 1ïŒ0.6ïŒ ïŒ | 41 |
ããŒã¢ã㌠ïŒç¬¬2äžä»£2016ïœïŒ | 1939 | 79 | 57ïŒ80ïŒ ïŒ | 14ïŒ20ïŒ ïŒ | 0 | 8 |
第äžäžä»£ 2017ïœ | 1583 | 33 | 31ïŒ100ïŒ ïŒ | 0ïŒ0ïŒ ïŒ | 0 | 2 |
åèš | 6903 | 303 | 179 | 72 | 1 | 51 |
ããã¯ãåºæ¬ã®3ã€ã®ããªãœããŒã«é¢ããããŒã¿ã§ãã
第2äžä»£ã¯ç¬¬1äžä»£ã®åŒ±ç¹ãå
æãã¹ãæ¹è¯ãããã®ã§ããããã®ç¬¬2äžä»£ãšæ¯ã¹ãŠãåœéœæ§ãŒããåœé°æ§ãŒããšå§åçã«åã£ãŠããã®ãããããŸããã
ãŸãã第2äžä»£ã¯SNPãäœ¿ãæ€æ»ã§ãããããŒã¢ããŒïŒã¢ãªãªãµïŒã¯ã¿ãŒã²ããã¢ã¬ã€ãšãã£ãŠãã€ã¯ãã¢ã¬ã€ã䜿ã£ãŠããæ€æ»ãããã©ãïŒããã©ïŒã¯ã¿ãŒã²ããã·ãŒã¯ãšã³ã¹ãšããæ¬¡äžä»£ã·ãŒã¯ãšã³ãµãŒãäœ¿ãæ¹åŒã§ãã
æ¹è¯çãªã®ã§ç²ŸåºŠãäžãã£ãŠããŸã2
1äžäººçšåºŠã®åºæ¬æ€æ»ãšæ§æè²äœæ€æ»ã®è«æå ±åã§ãã
åœé°æ§ã¯ãŒããT21,T18ã«é¢ããŠã¯åœéœæ§ãŒããéœæ§çäžç100ïŒ
ãšãªã£ãŠããŸãã
åºæ¬æ€æ» ïŒ13/18/21ããªãœããŒïŒ | çäŸæ° | çµéèŠ³å¯ | æ£ | æåºŠ | éœæ§çäžç% | é°æ§çäžçïŒ |
---|---|---|---|---|---|---|
æ£åžž | 10280 | 10280 | 99.98ïŒ ïŒ95ïŒ CI 99.93-99.998%ïŒ | 100 | ||
ç°åžž | ||||||
T21 | 126 | 44 | 44 | 100ïŒ ïŒ95ïŒ CI 92-100%ïŒ | 100 | |
T18 | 24 | 10 | 10 | 100ïŒ ïŒ95ïŒ CI 69-100%ïŒ | 100 | |
T13 | 16 | 7 | 5 | 100ïŒ ïŒ95ïŒ CI 48-100%ïŒ | 71 | |
æ§æè²äœ | ||||||
ç°åžž | ||||||
45,X | 16 | 7 | 4 | 100ïŒ ïŒ95ïŒ CI 40-100%ïŒ | ||
47,XXX | 6 | 2 | 0 | |||
47,XXY | 10 | 4 | 1 | |||
47,XYY | 3 | 0 | - | |||
48,XXYY | 1 | 1 | 1 |
åœé¢ã§ã¯éºäŒåæ€æ»ãå«ããã®ãã¹ãŒããŒNIPT100ãšåŒãã§ããŸãããéºäŒåæ€æ»ãå«ãŸãªãåºæ¬æ€æ»ãåããå Žåã§ãã第1äžä»£ã第3äžä»£ãããéžã³ããã ããããã«ããŠããŸãã
é¢é£èšäºïŒããªãœããŒãšã¯ãSNPãäžå¡©åºå€åã«ã€ããŠããã€ã¯ãã¢ã¬ã€ãšã¯ãéœæ§çäžç
éºäŒåã®å€åã«ããèµ·ããèµ€ã¡ããã®çŸæ£ãæ€åºã§ãã
ã¹ãŒããŒNIPT100ã¯æ°ååºçå蚺æãåŸæ¥ã®13ã»18ã»21ããªãœããŒã«å ããŠã
ïŒã€ã®åŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçåçŸ€ã®æ€åºã«å ããŠã100çš®é¡ã®éºäŒåã®2000ã®ç
çå€ç°ã«æ¡å€§ããŸããã
ïŒå
šæè²äœæ€æ»ã¯å«ãŸããŠãããŸããããåžæã®å Žåã¯è¿œå æéïŒäžåã§æ¿ããŸãã
ïŒè²»çšã¯çšå¥ïŒïŒäžïŒååãšãªããŸãã
ïŒåŠåš ïŒé±ããåããããŸãã
ä»ãŸã§ã®NIPTã¯ãããã¡ããã®æè²äœã®æ°ã®ç°åžžã ããã¿ããã®ã§ããã
ããªãœããŒã¯æè²äœãéåžž2æ¬ãªãšããã3æ¬ã«ãªãããšã«ããèµ·ãããã®ã§ããã
äžçªæåãªã®ã¯ããŠã³çå矀ïŒ21ããªãœããŒïŒã§ããã¯21çªæè²äœã3æ¬ããããšã«ããçºçããŸãã
ã¹ãŒããŒNIPT100ã¯ã
ã»æ§æè²äœã®æ°ã®ç°åžžïŒç°æ°æ§ïŒã«ããèµ·ããçŸæ£
ããåºæ¬çãª13/18/21ã®3ã€ã®ããªãœããŒãã
ããªãœããŒïŒïŒïŒããŠã³çå矀ïŒ21ããªãœããŒïŒïŒ
ããªãœããŒïŒïŒïŒãšãã¯ãŒãºçå矀ïŒ18ããªãœããŒïŒïŒ
ããªãœããŒïŒïŒïŒãããŠçå矀ïŒ
ããæ§æè²äœã®æ°ã®ç°åžžïŒç°æ°æ§ïŒã«ããèµ·ããçŸæ£ãã
ã¿ãŒããŒçå矀ïŒã¢ããœããŒXïŒ (Monosomy X)
ããªãã« Xçå矀 (Trisomy X)
ã¯ã©ã€ã³ãã§ã«ã¿ãŒçå矀 (XXY)
XYYçå矀
XXYY çå矀
ã»æè²äœã®æ§é ç°åžžã«ããèµ·ããçŸæ£
ããåŸ®çŽ°æ¬ å€±çå矀ïŒåŸ®å°æ¬ 倱çå矀ïŒãã
DiGeorge syndrome (22q11.2)
1p36 deletion syndrome
Smith-Magenis syndrome (17p11.2)
Wolf-Hirschhorn syndrome (4p16.3)
ã«å ããŠ
ã»åäžéºäŒåçŸæ£ïŒéºäŒåã®ç
çããªã¢ã³ããããããçŸæ£ïŒ
ã»100éºäŒåã®2000ã®ç
çããªã¢ã³ã«ããèµ·ããçŸæ£
ã調ã¹ãããšãã§ããã®ãç¹åŸŽã§ãã
èµ€ã¡ããã®å 倩ç°åžžã埩ç¿ããã
äžã®å³ã¯ãçãŸããªããã«é害ããã€èµ€ã¡ããã®
é害ã®åå ã調æ»ãããã®ã§ãã
åºå žïŒAdapted from Stevenson, RE and Hall, J. Human Malformations and Related Anomalies, 2nd ed. Oxford University Press, Oxford,  2006
ãããã¿ããšãå
šäœã§ïŒïŒ
ã®èµ€ã¡ãããäœããã®é害ããã£ãŠçãŸã
ãã®ãã¡ã®10-15ïŒ
ãæè²äœã®ç°åžžã«ãããã®
8-12ïŒ
ãåºçåã®ææãªã©ã®å€å æ§
2-10ïŒ
ãåäžéºäŒåçŸæ£
20-25ïŒ
ãè€åæ§
40-60ïŒ
ãäžæ
ãšãªã£ãŠããŸãã
NIPTã¯æ¯äœè¡ã®äžã®èå
ç±æ¥ã®cell-free DNAãæ€æ»ããŠ
èµ€ã¡ããã®æè²äœã®æ°ã®ç°åžžã蚺æããæè¡ã§ããã(äžã®ã°ã©ãã®æè²äœç°åžžã®ãšãã)
ãã®å ã«ã¯ãèµ€ã¡ããã®éºäŒåãã»ã«ããªãŒDNAã§å šéšèªããããã«ãªãæä»£ãå°æ¥ããŸãã
ïŒéåžžã®NIPTã¯ãNIPTã®ãããããŒãžã«æžããŠããéããæçã®äžéšïŒ36å¡©åºïŒãèªã¿åã£ãŠãæè²äœã®ã©ã®éšåã«è©²åœããã®ããåæããŠããŸãã
ããããå°æ¥çã«ã¯ãã£ãšããããã®éºäŒåã®ç°åžžã«ããçŸæ£ããããããã«ãªãããšã§ãããã
ã§ãã®ã§ãã¹ãŒããŒ>NIPT100ãšåä»ããŸããã
第3äžä»£NIPTãšãç³ããŸãã
æ¬åœã¯monogenic NIPD åäžéºäŒåçŸæ£ç¡äŸµè¥²æ¯äœè¡èå
蚺æããšããã®ãæ£ããåŒç§°ã§ãã
ãããããéºäŒç ããšããããçŸæ£çŸ€ã察象ãšããéºäŒåæ€æ»ã§ãã
ã¹ãŒããŒNIPT100ã¯ãã®ãä»ãŸã§ã®13ããªãœããŒã»18ããªãœããŒã»21ããªãœããŒã«å ããŠ4ã€ã®åŸ®çŽ°æ¬ å€±ãšãåäžéºäŒåçŸæ£ããNIPTã§å€å¥ããã¹ã¯ãªãŒãã³ã°æ€æ»ã§ãã
ã¹ã¯ãªãŒãã³ã°ãããçŸæ£ã¯ãäžç床ããé床ã®è¡šçŸå(ãã®éºäŒåã«ãã®ç°åžžããããšãã®ç
æ°ãäžç床ããé床ã§çºçãããšãã颚ã«éºäŒåã®å€åãäœã®ç¹åŸŽãšããŠè¡šçŸãããããš)ãšé¢é£ããŠãããâçæŽ»ã®è³ªã«å€§ããªåœ±é¿ãåãŒããŸãã
ç°æ°æ§ïŒæè²äœã®æ°ã®ç°åžžãããªãœããŒãã¢ããœããŒïŒããã³åŸ®å°æ¬ 倱ïŒåŸ®çŽ°æ¬ å€±ïŒã®æ€åºãš
åäžéºäŒåçŸæ£ã®ã¹ã¯ãªãŒãã³ã°ãçµã¿åãããããšã«ããã
ã¹ãŒããŒNIPT100ã¯å°æ¥ã®äž¡èŠªã®ããã®åŠåš äžã®å
æ¬çãªãœãªã¥ãŒã·ã§ã³ãæäŸããŸãã
âããã§ããæè²äœããšãéºäŒåãã®éãã«ã€ããŠåŠç¿ãããïŒ
æè²äœã¯ã髿 ¡ã®çç©ãªã©ã§åºãŠããŸãããïŒçްèåè£ãããšãã«åã«å¢ããŠåããã£ãŠãã®ãçžã ãããã®ãã€ã§ãã
æè²äœãã»ãããšãã¢ããã³ãã·ãã·ã³ãã°ã¢ãã³ãããã³ã£ãŠããïŒçš®é¡ã®å¡©åºãã€ããæ žé žïŒããªããªãªãæ žé žïŒã䞊ãã DNAã®ç³žã«ãªããŸãã
ãã®DNAã®ã»ãããã²ãã ãšãããŸãã
ãããŠãã²ãã ã®äžã®ã¿ã³ãã¯ã«ç¿»èš³ãããŠå®éã«äœã®èšèšå³ãšããŠæ©èœããéšåãéºäŒåã§ãã
éºäŒåã¯ã²ãã ã®ãã£ãïŒïŒ ãããªãã®ã§ãïŒïŒäººäœã«ã¯çŽïŒïŒïŒïŒïŒã®éºäŒåããããŸãã
ä»ãŸã§ã®ããªãœããŒã®æ€æ»ã¯æè²äœïŒæ¬ãšãã倧ããªåäœãå¢ããŠãããã©ãããèŠããã®ã§ããã
第ïŒäžä»£ã®ã¹ãŒããŒNIPT100ã¯ãéºäŒåã®å¡©åºé åãå€ãã£ãŠããŸã£ãããäžéšãªããªã£ããããŠããããšã«ããçããçŸæ£ãã¿ãããšãã§ããŸãã
âãªãå¡©åºé åãå€ãããšç æ°ã«ãªãã®ïŒ
äžã€ã®éºäŒåã®å¡©åºã®äžŠã³æ¹ãå€ãã£ãŠããŸãããšã«ãã£ãŠãéºäŒæå·ãå€ãã£ãŠããŸãããã§ãã
âéºäŒæå·ã£ãŠãªãã«ïŒ
ã¢ããã³ãã·ãã·ã³ãã°ã¢ãã³ãããã³ãšããïŒçš®ã®å¡©åºãDNAã«ã¯ããã®ã§ããããã®å¡©åºãïŒã€ã»ããã«ãªã£ãŠã¢ããé žãšå¯Ÿå¿ããŠããŸãã
ããªãã¬ããã»ã³ãŒããšåŒã°ããããããéºäŒæå·ããšãããŸãã
å¡©åºãããã£ãŠããŸã£ãŠããå¶ç¶åãã¢ããé žãšå¯Ÿå¿ããŠãããšãã§åœ±é¿ããªãå Žåããããã
å¡©åºãå€ãã£ãŠããŸã£ãŠã¢ããé žãããã£ãŠããŸãããããã¿ã³ãã¯ã®éèŠãªéšåã ãšæ£åžžã«æ©èœããªããªã£ãŠããŸãããšããããŸãã
ã³ãã³ã¯ïŒã€ã®å¡©åºé åã®åäœã®ããšããããŸãããã¹ãããã»ã³ãã³ãšãã£ãŠã¢ããé žãã€ãªããã®ãããã§ãããªããããšããæä»€ãåºãã³ãã³ããããŸãã
ããããã³ãã³ãã§ããŠããŸããšããããå ã¯äœãããªãç°åžžãªããã±ããã§ããŠæ©èœåªå€±ããŠããŸããŸãã
ããããããšã«ããèµ·ããèµ€ã¡ããã®çŸæ£ãã¡ãæ€æ»ã§ããããã«ãªã£ããšããããšã§ããé¢é£èšäºïŒèå åç»ãåäžéºäŒåçŸæ£ç¡äŸµè¥²æ¯äœè¡èå 蚺æ
ã©ãããé¢šã«æ€æ»ããã®ïŒ
ã¹ãŒããŒNIPT100ã«ã¯
æ¯äœã®è¡æ¶²ãµã³ãã«ãšã
çç©åŠçç¶èŠªããã®å£è
ç²èã¹ã¯ããµã³ãã«ãå¿
èŠãšãªããŸãã
æ¯äœã®è¡æ¶²ã«ã¯ãæ¯èŠªãšèå
ã®äž¡æ¹ããã®ã»ã«ããªãŒDNAãå«ãŸããŠããŸãã
ãã®ã»ã«ããªãŒDNAããéºäŒçå€ç°ã®å¯èœæ§ããªããç¶èŠªã®DNAãµã³ãã«ãšãšãã«åé¢ããã³æ¬¡äžä»£ã·ãŒã¯ãšã³ãµãŒã§åæããŸãã
次ã«ãæŽç·Žããããã€ãªã€ã³ãã©ããã£ã¯ã¹ã¢ã«ãŽãªãºã ã䜿çšããŠãèå
ãåäžéºäŒåçŸæ£ãæã€ãªã¹ã¯ãèšç®ããŸãã
éºäŒåè§£æã®ç¹é·
ç¬èªã®éºäŒçããã³åæããŒã«ã䜿çšããŠãã¿ãŒã²ãããçµã£ãæ¿çž®ã𿬡äžä»£ã·ãŒã±ã³ã¹ïŒNGSïŒã䜿çšããŠãâéžæããã²ãã é åããã»ã«ããªãŒDNAãã©ã°ã¡ã³ãããã£ããã£ãã«ãŠã³ããåæããŸããâäž»ãªæ©èœã¯æ¬¡ã®ãšããã§ãã
ïŒïŒãã¹ãããã©ãŒãã³ã¹ã«åœ±é¿ãäžããè€éãªã¢ãŒããã¯ãã£ãæã€ã²ãã é åãåé¿ããããã«ç¹å¥ã«èšèšãããç¬èªæè¡ã䜿çšããŠããŸããâããã«ãããä»ã®NIPTã«é¢é£ããåé¡ãå æããã粟床ãšç²ŸåºŠãåäžããŸãã
ïŒïŒé«ãèªã¿åãæ·±åºŠ
ã·ãŒã¯ãšã³ãµãŒã§èªã¿åãåæ°ã®ããšã深床ãšãããŸãã
èªã¿åãåæ°ãå€ããã°å€ãã»ã©æéãã³ã¹ããããããŸããæ£ç¢ºæ§ã¯å¢ããŸãã
ãããã®ãã©ã°ã¡ã³ãã¯ãNGSã䜿çšããŠæ°çŸåã«ãŠã³ããããéåžžã«é«ãçµ±èšç²ŸåºŠãšç²ŸåºŠãå®çŸããŸãã
ïŒïŒæ£ç¢ºãªèå
åç»
ã²ãã ããã®æ¯äœããã³èå
ã®DNAã«ãŠã³ãã®é«ãèªã¿åãæ·±åºŠã䜿çšããŠãâã»ã«ããªãŒDNAãžã®èå
ã®å¯äžãæ£ç¢ºã«æž¬å®ããŸãã
æ£ç¢ºãªèå
åç»æž¬å®ã¯ã誀ã£ãçµæã«ãªããªãããã«å°ããŸãã
4.ç¬èªã®ãã€ãªã€ã³ãã©ããã£ã¯ã¹ãã€ãã©ã€ã³
åãã¹ãããçæãããã·ãŒã±ã³ã¹ã»ããŒã¿ãåæããŸãã
ãã«ããšã³ãžã³åæã«ãããç°æ°æ§ãåŸ®å°æ¬ 倱ãèå
ã®æ§å¥æ€åºã®æåºŠãšç¹ç°åºŠãåäžããŸãã
ã¹ãŒããŒNIPT100ã®ä¿¡é Œæ§ã¯ã©ããªã®ïŒ
第3äžä»£NIPTã§ã¯ããŸããåºæ¬ãããªãœããŒãšåŸ®çŽ°æ¬ å€±ããå§ããŸããã®ã§ã1äžäººãè¶
ãããããã®ããã©ãŒãã³ã¹ã«ã€ããŠã¯ããŒãžäžéšã§è¿°ã¹ãŸããã
ãã®è¡šã¯ããããããéºäŒåçŸæ£ãå¯Ÿè±¡ã«æ€æ»ãæ¡å€§ããããšã«2000äººèŠæš¡ã®ããã©ãŒãã³ã¹ãèŠããã®ã§ãã
詊æ | cell free DNAãšç¶ã®DNA | 䟵襲çã«åŸãããåºç忀æ»ã®è©Šæ | ãµã³ã¬ãŒæ³ã§ç¢ºå® | çäžçïŒ |
åèš | 2033 | |||
ããªãœããŒ21 | 22 | 22/22 | 100 | |
18ããªãœã㌠| 4 | 4/4 | 100 | |
13ããªãœã㌠| 1 | 1/1 | 100 | |
æ§æè²äœç°æ°æ§ | 2 | 2/2 | 100 | |
åŸ®çŽ°æ¬ å€± | 5 | 5/5 | 100 | |
éºäŒåå€ç°ãªã | 1497 | |||
å€ç°ãã | 536 | 496/496 | ||
å€ç°æ° | 613 | |||
æ°ççªç¶å€ç° | 87 | 87/87 | 100 |
é¢é£èšäºïŒãµã³ã¬ãŒæ³ãšã¯
éºäŒåå€ç°ã¯ã©ãããçŸæ£ãæ€æ»ã§ããã®ïŒ
100éºäŒåã®2000ã®å€ç°ïŒç çããªã¢ã³ãïŒãæ€æ»å¯èœã§ãã
ã䞡芪ãç çéºäŒåãä¿å ããŠããªããïŒãšããæ€æ»ãšãèµ€ã¡ããã ããæ°ççªç¶å€ç°ã§ç°åžžãæã£ãŠããªããã©ããã調ã¹ãããšãã§ããŸãã
ïŒïŒ3-ã¡ãã«ã¯ãããã«CoAã«ã«ããã·ã©ãŒãŒæ¬ æçãMCCC1ã
ïŒïŒ3-ã¡ãã«ã¯ãããã«CoAã«ã«ããã·ã©ãŒãŒæ¬ æçãMCCC2
ïŒïŒç¡Î²-ãªãã¿ã³ãã¯è¡ç
ïŒïŒèªéçã¹ãã¯ãã©ã ã»é¢ç¯æçž®ã»ãŠããã
ïŒïŒåžžæè²äœå£æ§åå€çºæ§å¢èè
ïŒïŒãã«ãã»ããŒãã«çå矀12å
ïŒïŒããŒã¿ãµã©ã»ãã¢
ïŒïŒã«ããã³ç
ïŒïŒææ£èµ€è¡çèèžç
ïŒïŒïŒã¯ãªã°ã©ãŒã»ããžã£ãŒïŒCrigler-NajjarïŒçå矀
ïŒïŒïŒå¢èæ§ç·ç¶ç
ïŒïŒïŒç¬¬XIå 忬 ä¹ç
ïŒïŒïŒå®¶ææ§èªåŸç¥çµå€±èª¿ç
ïŒïŒïŒå®¶ææ§å°äžæµ·ç±
ïŒïŒïŒFANCGé¢é£ãã¡ã³ã³ãè²§è¡
ïŒïŒïŒã°ãªã·ã³è³ç
ïŒïŒïŒç³åç
â
¢åïŒã³ãŒãªãŒïŒCoriïŒç
ïŒ
ïŒïŒïŒç³åç
â
ŠåïŒTaruiç
ïŒ
ïŒïŒïŒGRACILE çå矀
ïŒïŒïŒNONAKAçç
ïŒïŒïŒã€ãœåèé
žè¡ç
ïŒïŒïŒãžã¥ããŒã«çå矀2å
ïŒïŒïŒæ¥åéšåè¡šç®æ°Žç±ç Herlitz å
ïŒïŒïŒã¬ãŒãã«å
倩é»å
é1å
ïŒïŒïŒã©ã€ãã£ãã现è圢æäžå
š
ïŒïŒïŒçãžã¹ãããã£ãŒãè¢åž¯ãåžžæè²äœå£æ§4
ïŒïŒïŒã¡ãŒãã«ã·ãããå°¿ç3å
ïŒïŒïŒå®¶ææ§LPLæ¬ æçé·é
ïŒïŒïŒ3-ããããã·ã¢ã·ã« CoA è±æ°ŽçŽ é
µçŽ æ¬ æç
ïŒïŒïŒã¡ãŒãã«ã·ãããå°¿ç(type Ib)
ïŒïŒïŒã¡ãŒãã«ã·ãããå°¿ç(MMAAé¢é£)
ïŒïŒïŒãã«ããã«ã¹ã«ãã¡ã¿ãŒãŒæ¬ æç
ïŒïŒïŒMPV17é¢é£èè³åããã³ã³ããªã¢DNAæ¯æžçå矀
ïŒïŒïŒç¥çµæ§ã»ãã€ããªããã¹ãã³ç
ïŒïŒïŒãã€ããŒãã³çå矀
ïŒïŒïŒé«ãªã«ããã³è¡ç
ïŒïŒïŒæ°çå
å¯è
çœè³ªãžã¹ãããã£ãŒ
ïŒïŒïŒä¹³å
ã¬ããµã ç
ïŒïŒïŒãã§ãã«ã±ãã³å°¿ç
ïŒïŒïŒæ©å°è³äœåœ¢æ
ïŒïŒïŒãªãœãœãŒã -ã·ã¹ãã€ã³ãããã¢ãŒãŒç°åžžçŸæ£(æ¿åç°éªšç)
ïŒïŒïŒãã«ãã³é
žè±æ°ŽçŽ é
µçŽ è€åäœæ¬ æç
ïŒïŒïŒç¶²èè²çŽ å€æ§çRLBP1
ïŒïŒïŒç¶²èè²çŽ å€æ§çDHDDS
ïŒïŒïŒã ã³å€ç³çåïŒãµã³ãã£ãªããçå矀ïŒ
ïŒïŒïŒéç¶èµ€è¡çç
ïŒïŒïŒã·ã§ãŒã°ã¬ã³ã»ã©ã«ãœã³ïŒSjögren-LarssonïŒçå矀
ïŒïŒïŒãã€ã»ãµãã¯ã¹ç
ïŒïŒïŒã¢ãã·ã£ãŒçå矀1Få
ïŒïŒïŒ3-ããããã·-3-ã¡ãã«ã°ã«ã¿ã«é
žè¡ç
ïŒïŒïŒãã«ãªãã·ãœãŒã βé
žåç³»é
µçŽ æ¬ æçïŒã¢ã·ã«âCoA ãªãã·ããŒãŒ (AOX) æ¬ æçïŒ
ïŒïŒïŒãšã«ã«ãã£âã°ãã£ãšãŒã«çå矀 (Aicardi-GoutiÚres syndrome; AGS)
ïŒïŒïŒã¢ã«ããŒãçå矀ïŒïŒžæè²äœé£éåïŒ
ïŒïŒïŒAlström çå矀
ïŒïŒïŒã¢ã³ããŒãã³çå矀
ïŒïŒïŒã¢ããã¿ãŒãŒæ¬ æç
ïŒïŒïŒã¢ã¹ãã©ã®ã³åæé
µçŽ æ¬ æç
ïŒïŒïŒã¢ã¹ãã«ãã«ã°ã«ã³ãµãã³å°¿ç
ïŒïŒïŒãã«ããŒã»ããŒãã«ïŒBardet-BiedlïŒçå矀ïŒBBS1é£é¢ïŒ
ïŒïŒïŒå
倩æ§ããªãã³ä»£è¬ç°åžžïŒããªããããŒãŒæ¬ æçïŒ
ïŒïŒïŒã«ãŒãã³ã¿ãŒçå矀ïŒçåæ§é èçž«åæ©æçåç ïŒ
ïŒïŒïŒã³ãã€ãã¬ãã¢ïŒç¶²è黿ãžã¹ãããã£ãŒïŒ
ïŒïŒïŒã·ããªã³æ¬ æç
ïŒïŒïŒããã³ã³ããªã¢å¿ççïŒCombined Oxidative Phosphorylation Deficiency 3
ïŒïŒïŒå
倩æ§Nçµååç³éåæç°åžžçIå
ïŒïŒïŒéçå
倩æ§å¥œäžçæžå°çïŒSCNïŒ3åãKostmannç
ïŒïŒïŒãã¡ã³ã³ãè²§è¡
ïŒïŒïŒãŽãŒã·ã§ç
ïŒïŒïŒã°ã«ã¿ã«é
žè¡çïŒå
ïŒïŒïŒç³åç
Iå G6PC
ïŒïŒïŒç³åç
IBå SLC37A4
ïŒïŒïŒéºäŒæ§ãã«ã¯ããŒã¹äžèç
ïŒïŒïŒãã¢ã·ã¹ãã³å°¿çcblEå
ïŒïŒïŒHydrolethalus çå矀
ïŒïŒïŒå
倩æ§éé±ç¬1å
ïŒïŒïŒããã³ã³ããªã¢è³ççãLeigh(ãªãŒ)çå矀ãFrench-Canadian type
ïŒïŒïŒéºäŒæ§çœè³ªè³çãvanishing white matterïŒVWMïŒwith leukoencephalopathy
ïŒïŒïŒè¢åž¯åçãžã¹ãããã£ãŒ2Eå
ïŒïŒïŒãªãžã³å°¿æ§ã¿ã³ãã¯äžèç
ïŒïŒïŒã¡ãã«ããã³é
žè¡çãcbICå
ïŒïŒïŒã¡ãã«ããã³é
žè¡çãcbIDå
ïŒïŒïŒã¡ãã«ããã³é
žè¡çãMutå
ïŒïŒïŒã ã³å€ç³çâ
¡åïŒãã³ã¿ãŒçå矀ïŒ
ïŒïŒïŒã ã³å€ç³çIIIcå
ïŒïŒïŒå
倩æ§ããªãããŒã(ããªãã¥ãã©ãŒããªãããŒ)
ïŒïŒïŒç¥çµã»ãã€ããªããã¹ãã³ç(CLIN8é£é¢)
ïŒïŒïŒç¥çµã»ãã€ããªããã¹ãã³ç(TPPé£é¢)
ïŒïŒïŒãªãŒã¡ã³çå矀ïŒRAG2é£é¢ïŒ
ïŒïŒïŒãªã«ããã³ã¢ãããã©ã³ã¹ãã§ã©ãŒãŒæ¬ æç
ïŒïŒïŒãã³ãã¬ããçå矀
ïŒïŒïŒæ©å°è³äœåœ¢æ1Aå
ïŒïŒïŒæ©å°è³äœåœ¢æ2Då
ïŒïŒïŒåçºæ§ç·æ¯æ©èœäžå
šçå矀ïŒDNAH5é£é¢ïŒ
ïŒïŒïŒåçºæ§ç·æ¯æ©èœäžå
šçå矀ïŒDNAI1é£é¢ïŒ
ïŒïŒïŒåçºæ§é«ã·ã¥ãŠé
žå°¿ç3å
ïŒïŒïŒç¶²èè²çŽ å€æ§ç25
ïŒïŒïŒT-B- éçè€åå
ç«äžå
šçïŒDCLRE1CCLRE1CéºäŒåïŒ
ïŒïŒïŒT-B- éçè€åå
ç«äžå
šçïŒIL2RGéºäŒåïŒ
ïŒïŒïŒãã£ã³ã©ã³ãåå
倩æ§ããããŒãŒçå矀
ïŒïŒïŒïŒStuve-Wiedemann çå矀
ïŒïŒïŒïŒä¹³å
æçºçåã©ã€ãœãŸãŒã é
žæ§ãªããŒãŒïŒlysosomal acid lipase, LALïŒæ¬ æçïŒãŠã©ã«ãã³ç
)
- 以äžã®çŸæ£100éºäŒåã®2000ã®å€ç°ïŒç
çããªã¢ã³ãïŒãæ€æ»å¯èœã§ãããã®äžã«ã¯ãæ°çå
ãã¹ã¹ã¯ãªãŒãã³ã°ã宿œãããŠãããã®ããããŸãã
æè²äœãéºäŒåã®ç°åžžã¯ãªãèµ·ããã®ïŒ
æè²äœã®ç°åžžããªãèµ·ããã®ã
现èåè£ã®æãçæ®çŽ°èïŒç²Ÿåã»åµåïŒãäœãã®ã¯éåžžã®åè£ãšã¯éãæžæ°åè£ãšèšã£ãŠã
22æ¬ã®åžžæè²äœãš1æ¬ã®æ§æè²äœã®ã»ãããããªã2ã»ããã®æè²äœã
1ã»ãããã€ã«åããããšãããšããç¹æ®ãªåè£æ¹æ³ãåããŸãããã®ãšã亀åãããåé¢ãããããã®ã§ããã
ãããããŸããããªããšçŸæ£ãåŒãèµ·ãããŸãã
ãããã¯å€§ããäºã€ã«åé¡ãããŸããäžã€ã¯æè²äœã®éšåçãªç°åžžïŒæ§é ç°åžžïŒã§ãé垞亀åã®å€±æã«ãã£ãŠåŒãèµ·ããããããšãå€ãã§ãã
éšåããªãœããŒïŒéè€ïŒã»éšåã¢ããœããŒïŒæ¬ 倱ïŒã»è»¢åº§ãªã©ãæããããŸããäºã€ç®ã¯ç°æ°äœïŒæ°çç°åžžïŒãšåŒã°ããæè²äœ1æ¬åäœã®äžè¶³ãããã¯éå°ã«ããç°åžžã§ãã
äžå®å šãªæè²äœã®åé¢ã«ãã£ãŠåŒãèµ·ããããããšãå€ããšãããŠããŸããéåžžæè²äœã¯2æ¬ã§å¯ŸããªããŠããïŒãã€ãœããŒãšãããŸãïŒãã
ããã1æ¬ã«ãªãã®ããã¢ããœããŒãã3æ¬ã«ãªãã®ããããªãœããŒãã§ããæè²äœã«ã¯ãã³ãããã£ãŠããããå¢ã«çè ïŒpïŒãšé·è ïŒqïŒã«ãããããŸãã
äŸãã°5çªæè²äœã®çæ¹ã®çè ãæ¬ 倱ããããšã5pã¢ããœããŒãšããã
5p-ïŒãããŒãã€ãã¹ïŒãšè¡šèšããããŸããæè²äœã®æ°ã圢æ ã®ç°åžžã䌎ããªãéºäŒåã®ç°åžžã«ããç æ°ã¯éºäŒåçŸæ£ã«ã
åå ã®æããã§ãªãå 倩å¥åœ¢çå矀ã¯å¥åœ¢çå矀ã«åé¡ãããŸããåžžæè²äœããªãœããŒãšã¯ïŒ
ããªãœããŒã¯ã»ãšãã©ã®å Žåäžæ¹çã«å¥³æ§ã®å¹Žéœ¢ã®é«ããšæ£ã®çžé¢ãããŸãã
åµåã¯å¥³æ§ãèçæããååšã现èåè£ããããçãŸãå€ãã£ãããããªã倧å€ç¹æ®ãªçްèã§ããããããã®çްèã¯äžã€åœããäžæ¥5äžãã50äžãæã®DNAæå·ãåããŠãããŸããã
DNAä¿®åŸ©é µçŽ ãããããããããŠãã¯åé¡ã«ãªããŸãããããããDNAä¿®åŸ©é µçŽ ã100äžåã«äžåçšåºŠã§ãšã©ãŒãèµ·ãããŸãã
ãã®ãããDNAæå·ã¯ã©ã®çްèã§ãèç©ãããŠããã®ã§ããã
éåžžã®çްèã¯æéçµéãšãšãã«æ»ãã§çãŸãå€ããçºãããã倧ããåé¡ã«ãªãäºã¯ãããŸãããããããåµåã¯DNAã®æå·ãç©ã¿éãªã£ãŠããäžæ¹ã§ããçºã
女æ§ã®å¹Žéœ¢ãšã ãæ£ã®çžé¢ããããšèšãããŠããŸããããåžžæè²äœãããªãœããŒãšãªããšããã®æè²äœã«ããéºäŒåã1.5åã«ãªãããã
èªã¿èŸŒãŸããã¿ã³ãã¯éãéåžžã®1.5åã«ãªã£ãŠæ§ã ãªåœ±é¿ãåãŒããšèããããŸããçè«çã«ã¯ã©ã®åžžæè²äœã«ãããªãœããŒã¯èµ·ããã®ã§ããã
åžžæè²äœã®å®å šãªããªãœããŒã¯ã
13çªæè²äœã»18çªæè²äœã»21çªæè²äœã®3çš®é¡ä»¥å€ã¯ãããŸãã«ããååšããŸããããã®çç±ã¯ãä»ã®åžžæè²äœã«ã¯éºäŒæ å ±ãå€ãããã
ããªãœããŒã«ããå€åãèŽæ»çãšãªãçåºããªããŸãã¯ãæ©æã«æµç£ãããããšãããŠããŸããåžžæè²äœã®ããªãœããŒã¯æè²äœã«å«ãŸããéºäŒåãå€ããã°å€ãã»ã©ã
ãŸãéèŠãªéºäŒåãå«ãŸããæ°ãå€ãã»ã©éçã«ãªãåŸåã«ãããŸããæè²äœã®çªå·ã¯åºæ¬çã«ã¯ã
æè²äœã®ãµã€ãºã倧ããæ¹ããé çªã«æ¯ãããŠããã®ã§ãã(21çªãš22çªã¯å€§ãããšçªå·ãé転ããŠããŸã)ã
æè²äœã®ãµã€ãºãšéºäŒåã®éãéèŠæ§ã¯æ£ç¢ºã«é£åããã
åžžæè²äœã§äžçªéºäŒåã®æ°ãå°ãªãã®ã¯äžçªå°ãã21çªæè²äœã®337åã§ããã
2çªç®ã«å°ãªãã®ã¯18çªã®400åã»3çªç®ã13çªã®496åãšãªã£ãŠããã®ã§ããããã«å¯ŸããŠ21çªãšæè²äœã®ãµã€ãºã®è¿ã22çªã¯ã
éºäŒåæ°701åããŸã20çªã¯710åãšãªã£ãŠããŸãããã®ããã«éºäŒåæ°ãå°ãªãã
131821ã®3çš®é¡ã®æè²äœã¯å®å šãªããªãœããŒã§ãã
çåãžã®æªåœ±é¿ãæ¯èŒçå°ããåºçæãŸã§çåã§ããå¯èœæ§ã¯ããçšåºŠããã®ã§ããã
ãã以å€ã®åºçäŸãçšãªã®ã¯çåãžã®æªåœ±é¿ã倧ãããããããšèããããŠããŸãã1ãã6ãšãã倧ããæè²äœã§ã¯éšåããªãœããŒé€ããŠ
ã¢ã¶ã€ã¯ãå«ããŠèŽæ»ã§1ããªãœããŒã«è³ã£ãŠã¯çåºã§ããŸãããåºçå¯èœãªåžžæè²äœããªãœããŒãã®ã§ãã
æµç£ã»æ»ç£ã§åºçåã«æ·æ±°ãããããšãå€ããäžçªè»œã21ããªãœããŒã§ã
7ïœ8å²ã¯åºçåã«æ·æ±°ããããšãããŠããŸãã1ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 2ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 3ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 4ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 5ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 6ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 7ããªãœã㌠ã¢ã¶ã€ã¯ã§ã®ã¿ããçšã«åºçäŸããïŒå®å šåã¯èŽæ»ïŒ 8ããªãœã㌠ããçšã«åºçäŸãã 9ããªãœã㌠ããçšã«åºçäŸãã 10ããªãœã㌠ã¢ã¶ã€ã¯ã§ã®ã¿ããçšã«åºçäŸããïŒå®å šåã¯èŽæ»ïŒ 11ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 12ããªãœã㌠ã¢ã¶ã€ã¯ã§ã®ã¿ããçšã«åºçäŸããïŒå®å šåã¯èŽæ»ïŒ 13ããªãœã㌠ãããŠçå矀 14ããªãœã㌠ã¢ã¶ã€ã¯ã§ã®ã¿ããçšã«åºçäŸããïŒå®å šåã¯èŽæ»ïŒ 15ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 16ããªãœã㌠ã¢ã¶ã€ã¯ã§ã®ã¿ããçšã«åºçäŸããïŒå®å šåã¯èŽæ»ïŒ 17ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 18ããªãœã㌠ãšãã¯ãŒãºçå矀ïŒ18ããªãœããŒïŒ 19ããªãœããŒ èŽæ»ïŒåºçå ±åãªãïŒ 20ããªãœã㌠ã¢ã¶ã€ã¯ã§ã®ã¿ããçšã«åºçäŸããïŒå®å šåã¯èŽæ»ïŒ 21ããªãœã㌠ããŠã³çå矀ïŒ21ããªãœããŒïŒ 22ããªãœã㌠ããçšã«åºçäŸãã Trisomy 21 (Down syndrome)
21çªæè²äœã®ã³ããŒæ°ãå€ãããšã§èµ·ãããããŠã³çå矀ïŒ21ããªãœããŒïŒãšãåŒã°ããŸãã
éºäŒåã®åé¡ã§èµ·ããç¥çé害ãšããŠã¯æãå€ãã®ãããŠã³çïŒ21ããªãœããŒïŒã§ãã
ããŠã³çå矀ïŒ21ããªãœããŒïŒã®æ£è ããã¯ããŸããŸãªçšåºŠã®ç¥çéå®³ãæ±ããå¹³åIQã¯50ã§ãããŸããããŠã³çå矀ïŒ21ããªãœããŒïŒã®äžã«ã¯å 倩æ§å¿çŸæ£ãªã©ã®èåšéå®³ãæ±ãããåãããããŠã
å€ç§çãŸãã¯å»åŠçã«æ²»çãå¿ èŠãšãªã£ããããŸãããŸãããªãã«ã¯èŠèŠé害ã»èŽèŠé害ãèŠãããããšãããã
倧ãããªã£ãŠããèªç¥æ©èœé害ãèªããããããšããããŸããTrisomy 18 (Edwards syndrome)
18çªæè²äœã®ã³ããŒæ°ãå€ãããšã§èµ·ããããšãã¯ãŒãºçå矀ïŒ18ããªãœããŒïŒãšåŒã°ããŸãã
ã»ãšãã©ãè³ã»å¿èããã®ä»ã«å å€©çæ¬ æãè€æ°æ±ããŠããŸãã
åå®®å ã§ã®çºè²äžå šãäžè¬çã§ãå€ãã¯æµç£ãæ»ç£ãšãªããŸããçããŠçãŸããŠã1æ³æªæºã§äº¡ããªãããšãå€ãã£ãã®ã§ãããæè¿ã§ã¯å¯¿åœã¯å¹³å6æ³ãããã«ã®ã³ãŠããŸãã
çåããŠããåäŸãã¡ã¯ãç¥çé害ã»çºè²é害ãšããåé¡ã«çŽé¢ããŸããtrisomy 13 (Patau syndrome)
13çªç®ã®æè²äœã®ã³ããŒæ°ãå€ãããšã§èµ·ããããããŠçå矀ãšãåŒã°ããŸãã
ã»ãšãã©ã®åäŸãã¡ã¯è³ããã®ä»ã®èåšã«å å€©çæ¬ æãæ±ããŸãã
å€ãã¯æµç£ãæ»ç£ãšãªãçããŠçãŸããŠã1å¹Žæªæºã§äº¡ããªãããšãå€ãã§ããåºæ¬æ€æ»ãšæ§æè²äœã®ç°æ°æ§æ€æ»ã®ç²ŸåºŠã¯ïŒ
æåºŠïŒ ç¹ç°åºŠïŒ éœæ§çäžçïŒ é°æ§çäžçïŒ åžžæè²äœæ£åžž 99.98ïŒ 99.98 100 T21 100 100 T18 100 100 T13 100 71 æ§æè²äœæ£åžž 99.99 100 45,X 100 57 47,XXY – – – 47,XYY – – – 48,XXYY – – – åŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçå矀ã«ã€ããŠ
ã¹ãŒããŒNIPT100ã§æ€æ»å¯èœãª4çš®é¡ã®åŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçå矀ã®é »åºŠãåèšãããšã
ãã®4ã€ã®ããããã®åŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçå矀ã®åºç確çã¯çŽïŒå人ã«äžäººãšãªããŸããäºå人ã«äžäººã
ãããäœããšãšããããã
é«ããšæããã®ãã¯åã 人ã«ããç°ãªãã®ã§ãããããããã該åœããåäœã«ãšã£ãŠã¯åœããåœãããªãã¯ã0ã1ã®äžçã
確çã®äžçãšçŸå®ãšã®éã«ã¯åããããªãæºããããŸãã
çŸå®ã¯äœããããåé§ããã®ã§ããã ãããå®éã«åœãããã©ããæããŠã»ããã
ãšãããæèŠã¯ãã£ãŠãããã¹ãã§ãã£ãŠããããåããŠèªå·±æ±ºå®ããããšããèŠæ±ã
ééã£ãŠãããšæ±ºãã€ããããšã¯åºæ¥ãªããšæããŸããåŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçå矀ãšã¯ïŒ
åŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçåçŸ€ã¯æè²äœã®äžéšã®å°ããªæçããªããªãããšãåå ã§èµ·ããçŸæ£çŸ€ã§ãã
éåžžã®æè²äœæ€æ»ã§ã¯æ€åºã§ããŸãããããäžå®ã®æè²äœã«ç¹ç°çãã€äžè¬çã«èµ·ãããããç¥ãããéºäŒæ§çå矀ã«é¢é£ããŠããŸãã
ã»ãšãã©ã¯äž¡èŠªããã®éºäŒã§ã¯ãªããæ°ççªç¶å€ç°
ïŒç¥å ããåãç¶ãã ãã®ã§ã¯ãªã粟åãåµåãã§ãããšãã«ãããçªç¶å€ç°ã®ããšã§ãïŒã§èµ·ããã
å±éºå åãå®¶ææŽããããŸãããæ€æ»ã®å©çã¯ãªãã«ïŒ
å€ãã®åŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçå矀ã¯ã身äœç粟ç¥çåæ¹ã«é害ãããããã
æ·±å»ãªå¥åº·åé¡ãèµ·ãããŸããããŠã³çïŒ21ããªãœããŒïŒã¯çŽ1/500ã
ããã«å¯ŸããŠã¹ãŒããŒNIPT100ã§ããã4ãæã®åŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒã¯åç®ãããšçŽ1/2000ã
ãããå€ããšã¿ããå°ãªããšã¿ããã¯å人差ããããŸãã
åããèšã£ãŠããéããå°ãªããšåœãããªãã¯åäžã§ã¯ãããŸããã
çµ±èšåŠçã«å°ãªãæ°åã§ããåœãããåœãããªããã¯ãã®äººãããããŒããïŒã®äžçãªã®ã§ãããããã¯è¡æž ããŒã«ãŒãã¹ããè¶ é³æ³¢æ€æ»ã§ã¯æ€åºã§ããŸããã
ã¹ãŒããŒNIPT100ã§ã¯ãçµšæ¯æ€æ»ãçŸæ°Žæ€æ»ãšãã£ã䟵襲çãªæ€æ»ã«æ¯èŒããŠã
é䟵襲çãªæ€æ»ãªãã·ã§ã³ãšããŠåŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçå矀ãš100éºäŒåã®2000çš®é¡ã®ç çããªã¢ã³ãïŒå€ç°ïŒãæäŸããããŸãããªãã¹ãŒããŒNIPT100ïŒ
ã¹ãŒããŒNIPT100ã¯æ°ååºçå蚺æãåŸæ¥ã®13ã»18ã»21ããªãœããŒã«å ããŠã
ïŒã€ã®åŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒçåçŸ€ã®æ€åºãšã100çš®é¡ã®éºäŒåã®2000ã®ç çå€ç°ã«æ¡å€§ããŸããã
ïŒå šæè²äœæ€æ»ã¯å«ãŸããŠãããŸããåŠåš æã®ãããŒãžã¡ã³ããæ°çå ãè¿ããã«ãããæºåãããããšãã§ããããšãæå³ããŠããŸãã
ïŒã€ã«ããç€Ÿã®æäŸããïŒã€ãšã¯ç°ãªã£ãŠããŸãã®ã§ã泚æãã ãããâããªãã¡ã€ã»ãã©ã¹ãåŒãç¶ãæ±ããŸãã1p36æ¬ å€±çå矀
1p36ã®æ¬ 倱ãçºçé »åºŠã¯ 1/4,000-10,000ïŒ
æé·é害ã»é床粟ç¥çºéé æ»ã»é£æ²»æ§ãŠããããªã©ã®çç¶ãæ¥ãããŸãã
èœã¡ããŒãã çŒãå°ã£ãé¡ãªã©ã®ç¹åŸŽçãªé¡è²ãã»ãŒå šäŸã«èªããããŸãã
ä¹³å æã«ã¯çç·åŒµäœäžãåºä¹³äžè¯ãèªããããããšããããŸãã
å䜵çãšããŠãå 倩æ§å¿çŸæ£ã»é£èŽã»æèŠã»çœå éã»è¥æºãçšã«ç¥çµèœçްèè «ãçããããšããããŸãã4p16.3æ¬ å€±çå矀
Wolf-Hirschhornçå矀ãé »åºŠã¯1/9,6000ïŒ
ïŒçªæè²äœçè ã«äœçœ®ããéºäŒåçŸ€ã®æ¬ 倱ã«ããåŒãèµ·ããããçŸæ£ã§ã
é床ã®ç²Ÿç¥çºéã®é ããæé·é害ã»é£æ²»æ§ãŠãããã»å€çºåœ¢æ ç°åžžã䞻城ãšããããŸããç¹åŸŽçé¡è²ã»æé·é害ã»é床ã®ç²Ÿç¥çºéã®é ãã»çç·åŒµäœäžã»é£æ²»æ§ãŠãããã»æé£é害ãªã©ãèªããããŸãã
Smith-Magenisçå矀 (17p11.2)
æ£è æ°ã¯å šåœ2000人ã
17p11.2ã®æ¬ 倱ã«ããå 倩ç°åžžçå矀ã
ç¹åŸŽçãªé¡è²ãçãæãäžåºŠããé床ã®ç¥çé害ãç¹åŸŽçãªè¡åç¹æ§ãç¡ç é害ã瀺ãã
ä¹³å æã«çç·åŒµäœäžã瀺ããç¹åŸŽçãªé¡è²ãå䜵å¥åœ¢ã«æ°ã¥ãããã
é¡è²ã¯çé ãåé¡çªåºãçæ¯çåãè³ä»äœäœãå çŒè§éé¢ãæèŠãé¡é¢æ£äžäœåœ¢æãäžé¡çªåºãç¹åŸŽã
å¹ åºãçãæã䌎ããçºéã®é ããäžåºŠããé床ç¥çé害ã瀺ãã
è¡åã®é害ãäž»èŠãªåé¡ã§ãããå€åãè¡åæ§ãæ°åã®å€åãèªå·ä»å®³ãªã©ã瀺ãã
é床ã®ç¡ç é害ãç¹ã«ç¡ç ãªãºã é害ã瀺ãã22q11.2æ¬ å€±çå矀
DiGeorgeçå矀ãåºç1/4,000.
æ£è ã®80ïŒ ã¯å 倩æ§å¿çŸæ£ãå䜵ããèžè ºçºéé å»¶ã»ç¡åœ¢æã«ããå ç«äœäžãç¹åŸŽçé¡è²ã»å£èè£ã»è»å£èééäžå šã»äœã«ã«ã·ãŠã è¡çãªã©ã䞻城ãšããã
å¿çŸæ£ã¯ããã¡ããŒå城çã»èºåèåŒæ¬ æã»èºåèééã»äž»èŠäœèºåŽå¯åèã®å䜵ãªã©ãããã
ããã«å䜵ããå ç«äœäžãè¡å°æ¿æžå°ã»èºé«è¡å§ãªã©ã«ããæè¡æ»äº¡ã®å ±åãããã
æªã 广çãªæ²»çæ¹æ³ã¯æªç¢ºç«ãäºåŸäžè¯ã®çŸæ£ã§ããã
æ£è ã¯ããšãçåããŠããçºéé å»¶ã粟ç¥çŸæ£ã»çµ±å倱調çãªã©ã«ããçæŽ»é¢ã®é·æã«ãããæ¯éãæ¥ããçºéé å»¶ã»ç¹åŸŽçé¡è²ã»å 倩æ§å¿è¡ç®¡çŸæ£ã»å£èè£ã»èžè ºäœåœ¢æã»äœã«ã«ã·ãŠã è¡çãªã©ã倿§ãªèšåºçç¶ã䌎ãã
éçãªå¿å¥åœ¢ã«å ããäœèº«é·ã»è¡å°æ¿æžå°ã»æ±è¡çæžå°ã»çæ£ã»æèŠã»æ°ç®¡æ¯è»åçã»è³èçž®ã»çœå éã»å°è¶³ã»åŽåŒ¯çã»è å¥åœ¢ã»å°¿éäžè£ã»éèã»éŒ åŸãã«ãã¢ãªã©ã180以äžã®èšåºçç¶ãå ±åãããŠãããåŸ®çŽ°æ¬ å€±çå矀ã®ç²ŸåºŠã¯ïŒ
ãŸã Nãå°ãªãã®ã§ãããè«æåããŠãããªãã§ã¯ã5äŸã¿ã€ãã£ãŠ5äŸæ£èšºã§ããã
ã¹ãŒããŒNIPT100ã®è²»çšã¯ïŒ
ããããã質å
keyword: æè²äœç°åžžãåŸ®çŽ°æ¬ å€±ïŒåŸ®å°æ¬ 倱ïŒãããŠã³çïŒ21ããªãœããŒïŒåçŸ€ãæ°çå ãã¹ãã¹ã»ãã®ãã¹çå矀
é害ãå šæè²äœ NIPTãæ°ååºçå蚺æãé䟵襲çåºçåèšºææ°åã³ãããŠã€ã«ã¹ææããäžå®ãªæ¹ã ãž
åœé¢ã¯äºçŽèšºçããããããŠãããŸããã
åŠå©Šãããã¡ããè¶ãã«ãªãã®ã§ããšããšã€ã³ãã«ãšã³ã¶ãªã©ã®ææçãšäžŠåã§èšºçã§ããªãããã§ãã
å宀察å¿ã§å®å šäºçŽå¶ã§ãã®ã§ãå®å¿ããŠãè¶ããã ããã
æ°åã³ããã®èå»¶ã屿§ãããæéã¯ãã¿ãªããŸã®å®å šã®ããçµæé瀺ã¯ãã€ããŒãžã®ã¿ãšãããŠããã ããŸãã
äžäžéœæ§ã®å Žåã¯äœåºŠã§ããè¶ãã«ãªããŸãã®ã§ããå®å¿ãã ããã